{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:35:53Z","timestamp":1774899353955,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.jemermed.2012.02.042","type":"journal-article","created":{"date-parts":[[2012,5,16]],"date-time":"2012-05-16T08:34:35Z","timestamp":1337157275000},"page":"e221-e225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Hemorrhagic Gastritis with Dabigatran in a Patient with Renal Insufficiency"],"prefix":"10.1016","volume":"44","author":[{"given":"Shawn E.","family":"Fellows","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie M.","family":"Rosini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio G.","family":"Volz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jemermed.2012.02.042_bib1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"6 Suppl","key":"10.1016\/j.jemermed.2012.02.042_bib2","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jemermed.2012.02.042_bib3","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/archinte.1993.00410130073007","article-title":"Bleeding complications in oral anticoagulant therapy. An analysis of risk factors","volume":"153","author":"Van der Meer","year":"1993","journal-title":"Arch Intern Med"},{"issue":"4 Suppl","key":"10.1016\/j.jemermed.2012.02.042_bib4","doi-asserted-by":"crossref","first-page":"445S","DOI":"10.1378\/chest.114.5_Supplement.445S","article-title":"Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range","volume":"114","author":"Hirsh","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.jemermed.2012.02.042_bib5","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with ibesartan for prevention of vascular events (ACTIVE W): a randomized controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2012.02.042_bib6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Ximelagatran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation (SPORTIF-III): randomized controlled trial","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jemermed.2012.02.042_bib7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jama.293.6.681","article-title":"Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial","volume":"293","author":"Fiessinger","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2012.02.042_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/VHRM.S8942","article-title":"New options with dabigatran etexilate in anticoagulant therapy","volume":"6","author":"Maegdefessel","year":"2010","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jemermed.2012.02.042_bib9","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2012.02.042_bib10","series-title":"Product information. Pradaxa (dabigatran)","year":"2010"},{"key":"10.1016\/j.jemermed.2012.02.042_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.jemermed.2012.02.042_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1160\/TH10-06-0342","article-title":"Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays","volume":"105","author":"Lindahl","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jemermed.2012.02.042_bib13","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00003088-200847050-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate","volume":"47","author":"Stangier","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jemermed.2012.02.042_bib14","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMra044440","article-title":"Direct thrombin inhibitors","volume":"353","author":"Di Nisio","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jemermed.2012.02.042_bib15","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.thromres.2004.02.012","article-title":"Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin","volume":"113","author":"Casserly","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.jemermed.2012.02.042_bib16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000081505","article-title":"The ecarin clotting time, a universal method to quantify direct thrombin inhibitors","volume":"33","author":"Nowak","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.jemermed.2012.02.042_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-2125.2007.02899.x","article-title":"The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects","volume":"64","author":"Stangier","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jemermed.2012.02.042_bib18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jemermed.2012.02.042_bib19","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2014a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","author":"van Ryn","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jemermed.2012.02.042_bib20","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","article-title":"Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment","volume":"48","author":"Stangier","year":"2008","journal-title":"J Clin Pharmacol"},{"issue":"6 Suppl","key":"10.1016\/j.jemermed.2012.02.042_bib21","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jemermed.2012.02.042_bib22","unstructured":"European Medicines Agency product overview for Pradaxa. Available at: http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/pradaxa\/pradaxa.htm. Accessed February 5, 2011."},{"key":"10.1016\/j.jemermed.2012.02.042_bib23","unstructured":"Phytonadione. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex, expires 2011 Dec 31. Available at: http:\/\/www.thomsonhc.com. Accessed January 24, 2011."},{"issue":"6 Suppl","key":"10.1016\/j.jemermed.2012.02.042_bib24","doi-asserted-by":"crossref","first-page":"141S","DOI":"10.1378\/chest.08-0689","article-title":"Parenteral anticoagulants: American College of Chest Physicians (8th edition)","volume":"133","author":"Hirsh","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.jemermed.2012.02.042_bib25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2146\/ajhp080478","article-title":"Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage","volume":"67","author":"Rowe","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jemermed.2012.02.042_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tmrv.2006.08.002","article-title":"Anticoagulants and their reversal","volume":"21","author":"Schulman","year":"2007","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.jemermed.2012.02.042_bib27","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1345\/aph.1M447","article-title":"Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants","volume":"44","author":"Vavra","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jemermed.2012.02.042_bib28","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1213\/01.ANE.0000114072.71353.D5","article-title":"Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia","volume":"98","author":"Stratmann","year":"2004","journal-title":"Anesth Analg"},{"key":"10.1016\/j.jemermed.2012.02.042_bib29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/MBC.0b013e32832ff5aa","article-title":"Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin","volume":"20","author":"Fernl\u00f6f","year":"2009","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.jemermed.2012.02.042_bib30","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1161\/STROKEAHA.111.624650","article-title":"Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran","volume":"42","author":"Zhou","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.jemermed.2012.02.042_bib31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0049-3848(00)00397-2","article-title":"Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor","volume":"101","author":"Elg","year":"2001","journal-title":"Thromb Res"},{"key":"10.1016\/j.jemermed.2012.02.042_bib32","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled crossover study in healthy subjects","volume":"124","author":"Erenberg","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jemermed.2012.02.042_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2141.2004.04868.x","article-title":"Efficacy of standard dose and 30 ml\/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients","volume":"125","author":"Chowdhury","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jemermed.2012.02.042_bib34","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467912003332?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467912003332?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:29:51Z","timestamp":1760027391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467912003332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0736467912003332"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2012.02.042","relation":{},"ISSN":["0736-4679"],"issn-type":[{"value":"0736-4679","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hemorrhagic Gastritis with Dabigatran in a Patient with Renal Insufficiency","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2012.02.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}